<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04422314</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-00717</org_study_id>
    <nct_id>NCT04422314</nct_id>
  </id_info>
  <brief_title>ImmuneSense Lyme Study</brief_title>
  <official_title>ImmuneSense Lyme Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptive Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Adaptive Biotechnologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ImmuneSense Lyme is a study, which is designed to better understand the immune response to&#xD;
      Lyme disease. This is critically important because the immune system may be able to tell us&#xD;
      important information about how our own bodies detect and respond to the disease that current&#xD;
      tests cannot. Data collected from this study may accelerate the development of better&#xD;
      diagnostics for Lyme disease and improve outcomes for many.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Actual">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 29, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate sensitivity of T-Detect Lyme Assay relative to STTT and MTTT</measure>
    <time_frame>Baseline</time_frame>
    <description>Diagnostic sensitivity is defined as the percentage of persons who have a given disorder who are identified by the assay as positive for Lyme disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To demonstrate Specificity of T-Detect Lyme Assay relative to STTT and MTTT</measure>
    <time_frame>Baseline</time_frame>
    <description>Diagnostic specificity is defined as the percentage of persons who do not have a given condition who are identified by the assay as negative for Lyme disease.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">893</enrollment>
  <condition>Lyme Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Lyme disease testing cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Endemic, asymptomatic controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>Non-endemic, asymptomatic controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <description>Potential cross-reactive disease states</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <description>Lyme disease testing cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>T-Detect Lyme</intervention_name>
    <description>T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible participants include male and female participants, of any race and ethnicity, ages&#xD;
        7 and above (inclusive) at the time of enrollment. For Cohort 5 only, participants must be&#xD;
        18 years of age or older.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 1:&#xD;
&#xD;
          -  Participants at or above the age of 7&#xD;
&#xD;
          -  Arm A: Participants with an EM rash ≥ 5 cm (confirmed by Lyme disease independent&#xD;
             expert) with or without other signs and symptoms of Lyme disease&#xD;
&#xD;
          -  Arm B: Participants who do not have an EM rash &gt;/= 5 cm (either not confirmed by a&#xD;
             Lyme disease independent expert or lacking a rash), but who have signs and symptoms&#xD;
             suggestive of Lyme disease that warrants further testing, such as, but not limited to&#xD;
             fever, myalgias, malaise, lymphadenopathy, rigors, arthralgias, peripheral and&#xD;
             radiculoneuropathy, encephalopathy, intermittent arthritis, meningitis, heart block,&#xD;
             carditis, etc&#xD;
&#xD;
        Cohort 2:&#xD;
&#xD;
        - Individuals in general good health, who reside in Lyme disease endemic regions&#xD;
&#xD;
        Cohort 3:&#xD;
&#xD;
        - Individuals in general good health, who reside in a region that is non-endemic for Lyme&#xD;
        disease&#xD;
&#xD;
        Cohort 4:&#xD;
&#xD;
        Sourced from a sample repository&#xD;
&#xD;
          -  Biorepositories with documented consent from participants for secondary use of their&#xD;
             sample by a third party&#xD;
&#xD;
          -  Confirmed, documented diagnoses for one of the following diseases:&#xD;
&#xD;
          -  Viral: Epstein-Barr virus (EBV), cytomegalovirus (CMV), influenza, or COVID-19&#xD;
&#xD;
          -  Tick-borne diseases: babesiosis, rocky mountain spotted fever, anaplasmosis, or&#xD;
             ehrlichiosis&#xD;
&#xD;
          -  Bacterial infection: syphilis&#xD;
&#xD;
          -  Autoimmune/rheumatologic/neurologic diseases: Systemic Lupus Erythematous (SLE),&#xD;
             Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), chronic fatigue syndrome&#xD;
&#xD;
          -  For infections, active infections are preferred and should be prioritized. Past&#xD;
             infections will be acceptable for infections that are difficult to obtain.&#xD;
&#xD;
        Prospective collection Inclusion criteria&#xD;
&#xD;
          -  Confirmed, documented diagnoses for one of the following diseases:&#xD;
&#xD;
          -  Viral: Epstein-Barr virus (EBV), cytomegalovirus (CMV), influenza, or COVID-19&#xD;
&#xD;
          -  Tick-borne diseases: babesiosis, rocky mountain spotted fever, anaplasmosis, or&#xD;
             ehrlichiosis&#xD;
&#xD;
          -  Bacterial infection: syphilis&#xD;
&#xD;
          -  Autoimmune/rheumatologic/neurologic diseases: Systemic Lupus Erythematous (SLE),&#xD;
             Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), or chronic fatigue syndrome&#xD;
&#xD;
          -  For infections, active infections are preferred and should be prioritized. Past&#xD;
             infections will be acceptable for infections that are difficult to obtain.&#xD;
&#xD;
        Cohort 5:&#xD;
&#xD;
          -  Participants ages 18 and above&#xD;
&#xD;
          -  Arm A: Participants with an EM rash ≥ 5 cm (confirmed by Lyme disease independent&#xD;
             expert) with or without other signs and symptoms of Lyme disease&#xD;
&#xD;
          -  Arm B: Participants who do not have an EM rash &gt;/= 5 cm (either not confirmed by a&#xD;
             Lyme disease independent expert or lacking a rash), but who have signs and symptoms&#xD;
             suggestive of Lyme disease that warrants further testing, such as, but not limited to&#xD;
             fever, myalgias, malaise, lymphadenopathy, rigors, arthralgias, peripheral and&#xD;
             radiculoneuropathy, encephalopathy, intermittent arthritis, meningitis, heart block,&#xD;
             carditis, etc&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants will be excluded from the study if they meet any of the following&#xD;
             criteria:&#xD;
&#xD;
          -  Participant is a pregnant woman, prisoner, mentally disabled person, or ward-of-the&#xD;
             state.&#xD;
&#xD;
          -  Participant has any significant condition, laboratory abnormality, or psychiatric&#xD;
             illness that would prevent the participant from safely participating in the study.&#xD;
&#xD;
          -  Participant has been exposed to an investigational drug (new chemical entity) within&#xD;
             60 days prior to enrollment at the discretion of the investigator.&#xD;
&#xD;
          -  Participant has donated more than one pint or 500cc of blood in the past two months or&#xD;
             weight-based limits for pediatric populations.&#xD;
&#xD;
          -  Received the Lyme disease vaccine&#xD;
&#xD;
          -  Chronic infection with HIV, Tuberculosis, Hepatitis C, or Hepatitis B&#xD;
&#xD;
          -  Active malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thomas Manley, MD</last_name>
    <role>Study Director</role>
    <affiliation>VP, Clinical Development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Dines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sr. Medical Director, Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Hatboro</city>
        <state>Pennsylvania</state>
        <zip>19040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <zip>15683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <zip>16684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Kingwood</city>
        <state>West Virginia</state>
        <zip>26537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adaptive Biotechnologies Investigational Site</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erythema migrans rash</keyword>
  <keyword>bullseye rash</keyword>
  <keyword>early acute Lyme disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

